Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: Absolute levels or extent of lowering?

American Journal of Cardiology

Volumn 80, Issue 10, 1997, Pages 1287-1294

  Cullen, Paul ^a   Assmann, Gerd ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG EFFECT; HUMAN; HYPERLIPIDEMIA; PRIORITY JOURNAL;

ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PLASMAPHERESIS; PRAVASTATIN; REGRESSION ANALYSIS; RISK FACTORS; SIMVASTATIN;

EID: 0030776160     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00667-X     Document Type: Article

References (30)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
3. Gotto AM, Assmann G, Carmena R, Davignon J, Fernández-Cruz A, Paoletti R. The ILIB Lipid Handbook for Clinical Practice. Blood Lipids and Coronary Heart Disease. Houston: International Lipid Information Bureau, 1995.
4. Assmann G, Cullen P. Erkennung und Behandlung von Fettstoffwechselstörungen. Dtsch Ärztebl 1995;52(suppl.):1-12.
5. Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 1995;6:386-388.
6. Thompson GR. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis 1997;131:1-5.
7. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated levels of lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77:1179-1184.
8. Assmann G, Schulte H. Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-737.
9. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease - six years follow-up experience: the Framingham Study. Ann Intern Med 1961;55:33-50.
10. Kannel WB, Wilson PWF. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995;155:57-61.
11. Martin MJ, Browner WS, Wentworth D, Hulley SB, Kuller LH. Serum cholesterol, blood-pressure, and mortality - implications from a cohort of 361 662 men. Lancet 1986;2:933-936.
12. Lewis B. On lowering lipids in the post-infarction patient. J Intern Med 1991;229:483-488.
13. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Thorgeirsson G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H. Base line serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4s). Lancet 1995;345:1274-1275.
14. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
15. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1976;231:361.
16. Lipid Research Clinics Program. The Lipid Research Clinics Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-374.
17. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
18. Yamamoto A, Kojima SI, Haradashiba M, Toyota Y, Takamiya M, Tsushima M, Kishino BI, Koga N, Tatami R. Plasmapheresis for prevention and regression of coronary atherosclerosis. Ann NY Acad Sci 1995;748:429-440.
19. Watts GF, Burke V, Lewis B. Plasma low density lipoprotein-cholesterol levels and progression/regression of coronary atherosclerosis: a meta-regression analysis of angiographic trials. Br J Cardiol 1997;4:64-70.
20. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk-factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.
21. Keys A. Seven Countries: A Multivariate Analysis of Health and Coronary Heart Disease. Cambridge, MA: Harvard University Press, 1980.
22. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, Nelson J, Potter J, Rifkind B, Rossouw J, Shekelle R, Yusuf S. Report of the conference on low blood cholesterol mortality associations. Circulation 1992;86: 1046-1060.
23. Chen J, Campbell TC, Li J, Peto R. Diet, Life-Style and Mortality in China. Oxford, UK: Oxford University Press, 1990.
24. Chen Z, Peto R, Collins R, Macmahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. Br Med J 1991;303:276-282.
25. Peto R, Yusuf S, Collins R. Cholesterol lowering trials results in their epidemiological context. Circulation 1985;72:451.
26. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1996;308:367-373.
27. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995;91: 2274-2282.
28. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60.
29. Choleserol Treatment Trialists' (CTT) Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol 1995;75:1130-1134.
30. Pedersen TR, Tobert JA. Benefits and risks of HMG CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Safety 1996;1: 11-24.